Noradrenaline (Tartrate) (Sulfites Free) Aguettant (Noradrenaline Tartrate)

Noradrenaline works by directly stimulating α1, α2 and β1 adrenergic receptors. α1 activation causes peripheral vasoconstriction, raising systemic vascular resistance; β1 activation increases heart contractility and rate; α2 activation modulates endogenous norepinephrine release. Together these actions rapidly elevate arterial pressure.

The dose of noradrenaline is individualized. A qualified prescriber determines the infusion rate based on the patient’s hemodynamic response, target blood pressure and clinical condition. Dosing is typically expressed in micrograms per kilogram per minute and adjusted continuously during therapy.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

The primary alternative vasopressor is dopamine, which has dose‑dependent effects on dopaminergic, β‑ and α‑receptors. Noradrenaline provides more predictable α‑mediated vasoconstriction with less tachycardia, making it the preferred first‑line agent for most forms of shock, while dopamine may be chosen when renal perfusion is a specific goal.

Noradrenaline (Tartrate) (Sulfites Free) Aguettant must be stored refrigerated at 2‑8 °C. The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once removed from refrigeration, use within the time frame specified by the manufacturer.

The medication is given as an intravenous infusion, usually through a central venous catheter or a well‑secured peripheral line. It is administered continuously, with the infusion rate titrated to achieve the desired blood pressure and hemodynamic targets under close clinical monitoring.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis from extravasation, and pulmonary edema. Continuous blood pressure and cardiac monitoring are essential to detect these complications early and adjust therapy accordingly.

Noradrenaline is contraindicated in patients with known hypersensitivity to the product, uncorrected tachyarrhythmias, pheochromocytoma, or severe peripheral vascular disease where further vasoconstriction could cause tissue loss. Use should be avoided or used with extreme caution in these populations.